Critical Biologics Corporation Commences Clinical Testing of Solinex(TM)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Critical Biologics Corporation (CBC) today announced the successful enrollment of the first four patients in its “first-in-man” clinical trial for Solinex™, an intravenous formulation of recombinant human plasma gelsolin (rhu-pGSN). The trial is designed to assess the safety and pharmacokinetics of a single intravenous infusion of rhu-pGSN in critically ill patients with profound hypogelsolinemia in cohorts receiving progressively larger doses of the drug. It is planned to enter a total of 40 patients into the double blind, placebo controlled trial being conducted at a leading medical institution in Hong Kong.